Clearside Biomedical

Yahoo Finance • last month

Clearside Biomedical Files For Chapter 11 Bankruptcy

(RTTNews) - Clearside Biomedical, Inc. (CLSD) announced that it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the District of Delaware, with plans to pursue a structured auction and sale process of its busi... Full story

Yahoo Finance • last month

Clearside Biomedical files for Chapter 11

[Bankruptcy Chapter 11 is shown on the conceptual business photo] Andrii Dodonov * Clearside Biomedical (CLSD [https://seekingalpha.com/symbol/CLSD]) filed [https://seekingalpha.com/pr/20318035-clearside-biomedical-to-pursue-strategic-s... Full story

Yahoo Finance • last month

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential -... Full story

Yahoo Finance • last month

Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers

(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) s... Full story

Yahoo Finance • 4 months ago

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha S... Full story

Yahoo Finance • 4 months ago

Discover the top movers in Thursday's pre-market session.

Wondering what's happening in Thursday's pre-market session? Find an overview in this article. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT SNOA [https://www.chartmill.com/stock/quote/SNOA/profile] 109.0% The pre-... Full story

Yahoo Finance • 5 months ago

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 2... Full story

Yahoo Finance • 5 months ago

Chardan Capital downgrades Clearside Biomedical stock rating to Neutral

Investing.com - Chardan Capital Markets downgraded Clearside Biomedical (NASDAQ:CLSD) from Buy to Neutral and withdrew its price target as the company explores strategic alternatives. The downgrade comes as the stock has fallen 32% in the... Full story

Yahoo Finance • 5 months ago

Stifel downgrades Clearside Biomedical stock to Hold on cash concerns

Investing.com - Stifel downgraded Clearside Biomedical (NASDAQ:CLSD) from Buy to Hold and slashed its price target to $2.00 from $8.00 as the company faces severe financial constraints. The stock, which has plummeted 32% in the past week a... Full story

Yahoo Finance • 5 months ago

Clearside Biomedical to explore strategic alternatives amid cash concerns

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $65 million and impressive gross profit margins of 89%, announced Thursday it will explore strategic alternatives to ma... Full story

Yahoo Finance • 5 months ago

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Tria... Full story

Yahoo Finance • 6 months ago

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the  Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17... Full story

Yahoo Finance • 7 months ago

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced... Full story

Yahoo Finance • 9 months ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announce... Full story

Yahoo Finance • 9 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS®(XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in Chi... Full story

Yahoo Finance • 9 months ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics Directly to the Retina - ALPHARETTA, Ga.,... Full story

Yahoo Finance • 9 months ago

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention- Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Str... Full story

Yahoo Finance • 9 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprac... Full story

Yahoo Finance • 10 months ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Developmen... Full story

Yahoo Finance • 10 months ago

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprach... Full story